Skip to main content
Intermediate Technical IVT

carcinoembryonic antigen

Also written as: CEA — Carcinoembryonic Antigen

Tumor marker protein elevated in various cancers, particularly colorectal cancer, used for monitoring treatment response and detecting recurrence.

Full Definition

Carcinoembryonic antigen (CEA) is a glycoprotein normally produced during fetal development that becomes elevated in various malignancies, most notably colorectal cancer. CEA levels are primarily used for monitoring treatment response and detecting cancer recurrence rather than initial diagnosis, as elevated levels can also occur in benign conditions and smoking. In colorectal cancer management, CEA measurements are obtained preoperatively for staging purposes and postoperatively at regular intervals during surveillance. Rising CEA levels often precede clinical evidence of recurrence, making it a valuable tool for early detection of metastatic disease.

Usage

Usage note: Commonly abbreviated as CEA; specify normal reference ranges.

In Context

  • "Preoperative carcinoembryonic antigen level was markedly elevated at 45 ng/mL, suggesting advanced disease." — laboratory results interpretation
  • "Serial carcinoembryonic antigen monitoring detected early recurrence before radiological evidence appeared." — surveillance strategy

Also known as

CEA

Don't confuse with

CA 19-9 alpha-fetoprotein

Editors from these organisations have used our services since 1998

Reuters BBC Oxford University Press Penguin Random House Springer Microsoft Suncor Energy United Nations Fisher Investments IBM The Home Depot KODAK CHEVRON